Personalized Health Management Platform utilizing Sodium-Dependent Glucose Transporter Inhibitors
Legal Citation
Summary of the Inventive Concept
The inventive concept integrates Canagliflozin-based pharmaceutical compositions with digital health technologies to provide personalized dietary plans, monitor and control blood glucose levels, and prevent hypoglycemic events.
Background and Problem Solved
The original patent disclosed a pharmaceutical composition comprising Canagliflozin, but it did not explore the potential of this technology in digital health applications. This inventive concept addresses the limitations of traditional diabetes management by leveraging the benefits of sodium-dependent glucose transporter inhibitors in personalized health management.
Detailed Description of the Inventive Concept
The inventive concept comprises a system for predicting personalized dietary plans, methods for monitoring and controlling blood glucose levels, wearable devices for tracking physical activity and glucose levels, computer-implemented platforms for connecting patients with healthcare providers, and methods for identifying and preventing hypoglycemic events. These components utilize data from Canagliflozin-based pharmaceutical compositions to provide tailored nutritional recommendations, real-time feedback, and personalized alerts.
Novelty and Inventive Step
The new claims introduce a novel application of Canagliflozin-based pharmaceutical compositions in digital health technologies, providing a non-obvious integration of pharmaceutical and digital components to address unmet needs in diabetes management.
Alternative Embodiments and Variations
Alternative embodiments may include variations in the digital health technologies, such as using artificial intelligence or machine learning algorithms to analyze patient data, or integrating with existing electronic health records systems. Other variations may include using different sodium-dependent glucose transporter inhibitors or expanding the platform to address other health conditions.
Potential Commercial Applications and Market
The inventive concept has significant commercial potential in the digital health market, particularly in the diabetes management sector. The platform can be marketed to healthcare providers, patients, and payers, offering a comprehensive solution for personalized health management.
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Pharmaceutical compositions, digital health technologies, and diabetes management systems, with expertise in drug formulation, medical device integration, and patient monitoring platforms
Person of Ordinary Skill (PHOSITA) Profile
A professional with advanced degrees in pharmacy, biomedical engineering, or medical informatics, possessing knowledge of pharmaceutical formulations, digital health technologies, and diabetes management strategies
Obviousness Rationale
A PHOSITA would recognize that integrating digital health technologies with pharmaceutical compositions represents a predictable extension of existing medical management strategies. The combination of Canagliflozin-based pharmaceutical compositions with digital monitoring platforms addresses known challenges in diabetes management by providing personalized, real-time health interventions. The technical elements disclosed in the PTD represent logical combinations of existing pharmaceutical and digital health technologies that would be obvious to a skilled practitioner seeking comprehensive patient care solutions.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,559 |
|---|---|
| Title | Pharmaceutical composition comprising Canagliflozin, process of preparation and use thereof |
| Assignee(s) | Aurobindo Pharma Ltd |